Biotech Equities Are Finally Making Up Lost Ground
Insights - The biotech sector has taken a meaningful step towards making up lost ground. After consolidating between $290 and $320 for the last month, the NASDAQ … Continue Reading
Read nowAuthor Archives: Editorial Staff
AstraZeneca Takes Out ZS Pharma, Bodes Well for Relypsa
Research - AstraZeneca (AZN) will buy ZS Pharma (ZSPH) for $2.7 billion in cash, or $90 per share - a 42% premium to yesterday's close. Recall that Relypsa (RLYP) and its Veltassa (patiromer) are neck and neck as new entrants to the hyperkalemia market.
Read nowWell, That Was a Wild Week
Insights - Depending how you were positioned, this last week was one of the most entertaining, educational, and wild of the year. And the sell the news phenomenon … Continue Reading
Read now
Bluebird Bio Drops on Patient “Relapse” and Other Biotech Updates
Research - Shares of bluebird bio (BLUE) tumbled 15% mid-day when the company said at a medical conference that a beta-thalassemia patient who received Lentiglobin’s predecessor therapeutic … Continue Reading
PremiumIt Takes an Iron Stomach to Invest in Biotech Stocks
Insights - That was apparent yet again this week, with a slew of binary events that moved stocks in unexpected ways. Beginning with Zafgen (ZFGN). The developer … Continue Reading
Read now
Cempra’s Phase 3 Hit Its Primary Endpoints, But Not Without Caveats
Research - Positive top-line results from SOLITAIRE-IV, with some confounding safety outcomes, had Cempra Inc (CEMP) trading down on Friday morning by 25%.
PremiumBiotech Had a Compelling, Late-Week Rally
Insights - The iShares NASDAQ Biotech ETF (IBB) posted a major reversal from lows this Monday to close the week slightly in the green. That rally, most … Continue Reading
Read now